earticle

영어

Alendronate is a bisphosphonate that selectively inhibits osteoclast-mediated bone resorption. Dosing convenience is animportant element for the enhancement of patient compliance and the effective management of osteoporosis. The pur-pose of this study was to compare the effectiveness and compliance among alendronate pharmaceutical products(oralonce-weekly alendronate 70mg, daily alendronate 10mg, and once-weekly alendronate 70mg with Vitamin D3 2800IU) in terms of the change in bone mineral density (BMD), biochemical markers, and compliance estimates. A retro-spective chart review was conducted in patients with osteoporosis who received alendronate 70mg (Group 1), alendr-onate 10 mg (Group 2), or alendronate 70mg with Vitamin D3 2800 IU (Group 3) at the endocrinology department ofa hospital in Korea from Jan. 1, 1998 to Mar. 31, 2008. The primary endpoints were the increases in spine antero-pos-terior BMD T-score and femur trochanter BMD T-score, and the compliance of alendronate products. Secondary end-points included changes in bone turnover-related biochemical markers including bone-specific alkaline phosphatase,urinary N-terminal telopeptides (NTX) and osteocalcin, and in serum vitamin D3 concentration. There was no statisticaldifference in the BMD increase among the three alendronate products; spine BMD T-score increased by 0.49±0.52,0.39±0.48 and 0.50±0.41, and femur trochanter BMD T-score by 0.29±0.42, 0.21±0.53 and 0.24±0.22 in Group 1, 2 and3, respectively. With respect to the increases in femur trochanter BMD T-score and the decreases in NTX and osteocal-cin, 70mg once-weekly group was remarkably superior to 10mg daily group (p<0.05) The compliance of 70mgonce-weekly group was significantly higher than that of 10mg daily treatment group (p<0.001). In conclusion, allthree alendronate treatment groups were equivalent in effectiveness, and the compliance of 70 mg once-weekly groupwas better than that of 10 mg daily treatment group.